Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30

  • Milka Marinova
  • Martin Mücke
  • Lukas Mahlberg
  • Markus Essler
  • Henning Cuhls
  • Lukas Radbruch
  • Rupert Conrad
  • Hojjat Ahmadzadehfar
Original Article

Abstract

Introduction

Neuroendocrine tumors (NETs) have proven to be appropriate neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow-growing malignancies overexpress somatostatin receptors. The aim of this study was to evaluate changes in quality of life (QoL) of patients with P-NET following PRRT.

Methods

Sixty-eight patients with P-NET (31 female, mean age 61.4 y) underwent PRRT: 12 with NET of grade 1, 40 of grade 2, 8 of grade 3 (grade non-available n = 8). Prior to treatment, 39 patients showed ECOG 0, 26 patients ECOG 1, and three patients ECOG 2. Clinical assessment included evaluation of QoL and symptom changes using a standardized questionnaire (EORTC QLQ-C30) and was performed at baseline and every three months following each therapy cycle up to 12 months. Primary analysis compared QoL at baseline and after the fourth treatment cycle (N = 53).

Results

Up to four treatment cycles PRRT were performed for each patient. The median cumulative administered activity was 28.2 GBq. Primary analysis revealed that compared to baseline QoL was significantly improved revealing increased global health status (p = 0.008) and social functioning (p = 0.049) at the end of the study. Furthermore, fatigue and appetite loss showed a significant improvement after the last PRRT cycle (fatigue: p = 0.029, appetite loss p = 0.015). Sub-analyses showed that QoL was improved revealing increased global health status (3 months after first, second, and third treatment cycle p = 0.048, p = 0.002, and p < 0.001, respectively), emotional functioning (3 months after first-third cycle p = 0.003, p = 0.049, and p = 0.001, respectively) and social functioning (3 months after the first and second p < 0.001, and after the third cycle p = 0.015, respectively). Furthermore, some symptoms were significantly alleviated compared with baseline: fatigue (after first-third cycle p = 0.026, p = 0.050, and p = 0.008, respectively), nausea and vomiting (after first and second cycle p = 0.006 and p = 0.001, respectively), dyspnea (after third cycle p = 0.025), appetite loss (after first-third cycle p = 0.010, p = 0.001, and p = 0.009, respectively), constipation (after first-third cycle p = 0.050, p = 0.003, and p = 0.060, respectively).

Conclusion

PRRT is an effective treatment of P-NET improving QoL of patients in terms of increasing global health and mitigation of physical complaints.

Keywords

Pancreatic neuroendocrine tumor Peptide receptor radionuclide therapy Quality of life 177Lu-DOTATATE 

Notes

Acknowledgements

The authors acknowledge Guido Lüchters who provided valuable support and advice in all statistical questions at any time.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no financial or non-financial competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–81. https://doi.org/10.1016/j.bpg.2005.06.002.CrossRefPubMedGoogle Scholar
  2. 2.
    Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72. https://doi.org/10.1016/S1470-2045(07)70410-2.CrossRefPubMedGoogle Scholar
  3. 3.
    Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol: WJG. 2008;14:5377–84.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled Somatostatin analogue therapy of Gastroenteropancreatic cancer. Semin Nucl Med. 2016;46:225–38. https://doi.org/10.1053/j.semnuclmed.2015.12.003.CrossRefPubMedGoogle Scholar
  5. 5.
    Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–82. https://doi.org/10.2967/jnumed.114.148437.CrossRefPubMedGoogle Scholar
  6. 6.
    Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62. https://doi.org/10.1200/JCO.2005.08.066.CrossRefPubMedGoogle Scholar
  7. 7.
    Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35. https://doi.org/10.1007/s00259-011-1902-1.CrossRefPubMedGoogle Scholar
  8. 8.
    Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925–33. https://doi.org/10.1007/s00259-013-2677-3.CrossRefPubMedGoogle Scholar
  9. 9.
    Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grunwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183–90. https://doi.org/10.2967/jnumed.113.125336.CrossRefPubMedGoogle Scholar
  10. 10.
    van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, et al. Neoadjuvant treatment of nonfunctioning pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate. J Nucl Med. 2015;56:1647–53. https://doi.org/10.2967/jnumed.115.158899.CrossRefPubMedGoogle Scholar
  11. 11.
    Sabet A, Haslerud T, Pape UF, Ahmadzadehfar H, Grunwald F, Guhlke S, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:205–10. https://doi.org/10.1007/s00259-013-2547-z.CrossRefPubMedGoogle Scholar
  12. 12.
    Ezziddin S, Sabet A, Heinemann F, Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med. 2011;52:1197–203. https://doi.org/10.2967/jnumed.111.090373.CrossRefPubMedGoogle Scholar
  13. 13.
    Horsch D, Prasad V, Baum RP. Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides. J Clin Oncol. 2008;26:4517.CrossRefGoogle Scholar
  14. 14.
    Sabet A, Khalaf F, Yong-Hing CJ, Haslerud T, Ahmadzadehfar H, Guhlke S, et al. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin. 2014;53:54–9. https://doi.org/10.3413/Nukmed-0614-13-08.CrossRefPubMedGoogle Scholar
  15. 15.
    Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505–10. https://doi.org/10.1007/s00259-013-2601-x.CrossRefPubMedGoogle Scholar
  16. 16.
    Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Poppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61. https://doi.org/10.2967/jnumed.112.119347.CrossRefPubMedGoogle Scholar
  17. 17.
    Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43:1802–11. https://doi.org/10.1007/s00259-016-3382-9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. https://doi.org/10.1007/s00259-014-2893-5.CrossRefPubMedGoogle Scholar
  19. 19.
    Procopio G, Ratta R, de Braud F. Improved quality of life is the way to longer life. wwwthelancetcom/oncology. 2016;17:862–3.Google Scholar
  20. 20.
    Velanovich V. The association of quality-of-life measures with malignancy and survival in patients with pancreatic pathology. Pancreas. 2011;40:1063–9. https://doi.org/10.1097/MPA.0b013e31821ad8eb.CrossRefPubMedGoogle Scholar
  21. 21.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMedGoogle Scholar
  22. 22.
    Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual (3rd edition). 2001.Google Scholar
  23. 23.
    Cameron AC, Pravin KT. Microeconometrics Using Stata Revised Edition. Stata Press. 2010.Google Scholar
  24. 24.
    Rabe-Hesketh S, Skrondal A. Multilevel and Longitudinal Modeling Using Stata. Stata Press, 3rd ed 2012;1–2.Google Scholar
  25. 25.
    Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16. https://doi.org/10.1007/s00259-012-2330-6.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Maxwell JE, Sherman SK, Howe JR. Translational diagnostics and therapeutics in pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2016;22:5022–9. https://doi.org/10.1158/1078-0432.CCR-16-0435.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Jimenez-Fonseca P, Carmona-Bayonas A, Martin-Perez E, Crespo G, Serrano R, Llanos M, et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015;34:381–400. https://doi.org/10.1007/s10555-015-9573-1.CrossRefPubMedGoogle Scholar
  28. 28.
    Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004;22:2724–9. https://doi.org/10.1200/JCO.2004.10.016.CrossRefPubMedGoogle Scholar
  29. 29.
    Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005;6:765–72. https://doi.org/10.1016/S1470-2045(05)70325-9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mustian KM, Devine K, Ryan JL, Janelsins MC, Sprod LK, Peppone LJ, et al. Treatment of nausea and vomiting during chemotherapy. US Oncol Hematol. 2011;7:91–7.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013;39:610–21. https://doi.org/10.1016/j.ctrv.2012.12.014.CrossRefPubMedGoogle Scholar
  32. 32.
    Land SR, Walcott FL, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Symptoms and QOL as predictors of chemoprevention adherence in NRG oncology/NSABP trial P-1. J Natl Cancer Inst. 2016;108 https://doi.org/10.1093/jnci/djv365.
  33. 33.
    Fassino S, Amianto F, Sobrero C, Abbate DG. Does it exist a personality core of mental illness? A systematic review on core psychobiological personality traits in mental disorders. Panminerva Med. 2013;55:397–413.PubMedGoogle Scholar
  34. 34.
    Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26:867–81. https://doi.org/10.1016/j.bpg.2013.01.004.CrossRefPubMedGoogle Scholar
  35. 35.
    Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, et al. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nuclear Med. 2014;55:9–14. https://doi.org/10.2967/jnumed.112.112789.CrossRefGoogle Scholar
  36. 36.
    Luster M, Hanscheid H, Freudenberg LS, Verburg FA. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer. J Endocrinol Investig. 2012;35:21–9.Google Scholar
  37. 37.
    Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105–21. https://doi.org/10.1053/j.semnuclmed.2009.11.001.CrossRefPubMedGoogle Scholar
  38. 38.
    Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. J Nuclear Med. 2017;58:85–90. https://doi.org/10.2967/jnumed.116.183194.CrossRefGoogle Scholar
  39. 39.
    Dong C, Liu Z, Wang F. Peptide-based radiopharmaceuticals for targeted tumor therapy. Curr Med Chem. 2014;21:139–52.CrossRefPubMedGoogle Scholar
  40. 40.
    Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52:1361–8. https://doi.org/10.2967/jnumed.111.087932.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Milka Marinova
    • 1
  • Martin Mücke
    • 2
    • 3
    • 4
  • Lukas Mahlberg
    • 5
  • Markus Essler
    • 5
  • Henning Cuhls
    • 2
  • Lukas Radbruch
    • 2
  • Rupert Conrad
    • 6
  • Hojjat Ahmadzadehfar
    • 5
  1. 1.Department of RadiologyUniversity Hospital BonnBonnGermany
  2. 2.Department of Palliative MedicineUniversity Hospital BonnBonnGermany
  3. 3.Department of General Practice and Family MedicineUniversity Hospital BonnBonnGermany
  4. 4.Center for Rare Diseases Bonn (ZSEB)University Hospital of BonnBonnGermany
  5. 5.Department of Nuclear MedicineUniversity Hospital BonnBonnGermany
  6. 6.Department of Psychosomatic Medicine and PsychotherapyUniversity Hospital of BonnBonnGermany

Personalised recommendations